This is the authors' abstract. We don't add key points for this paper.
Primary cutaneous apocrine adenocarcinoma (PCAC) is an extremely rare neoplasm involving the sweat glands. Due to a lack of cases, there is no consensus for the systemic treatment of locally advanced or metastatic PCAC. Anti-androgen therapy may have activity in inoperable or metastatic PCAC with high androgen receptor (AR) expression.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Collette et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: